Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Thatcher

Showing results (221-230 of 289) with videos related to

Pageof 29
Sort By:
British Journal of Cancer|November 1, 1989
Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II studyN Thatcher, H Dazzi, R J Johnson, et al.
British Journal of Cancer|April 1, 1990
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II studyN Thatcher, H Dazzi, M Mellor, et al.
International Journal of Cancer|November 14, 1997
G1 control gene status is frequently altered in resectable non-small cell lung cancerD C Betticher, G R White, S Vonlanthen, et al.
British Journal of Cancer|September 14, 2006
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancerS C White, P Lorigan, G P Margison, et al.
British Journal of Cancer|June 1, 1988
A phase I and pharmacokinetic study of amphethinileD B Smith, C Ewen, J Mackintosh, et al.
Cancer|September 15, 1985
Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancerN Thatcher, R D James, W P Steward, et al.
British Journal of Cancer|July 31, 2008
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancerS Baka, R Califano, R Ferraldeschi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2006
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancerS Baka, C Manegold, E Buchholz, et al.
British Journal of Cancer|September 2, 2005
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinomaF Donskov, M Middleton, K Fode, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patientsH Sharma, N Thatcher, J Baer, et al.
Pageof 29

Showing results (221-230 of 289) with videos related to

Sort By:
Pageof 29
British Journal of Cancer|November 1, 1989
Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II studyN Thatcher, H Dazzi, R J Johnson, et al.
British Journal of Cancer|April 1, 1990
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II studyN Thatcher, H Dazzi, M Mellor, et al.
International Journal of Cancer|November 14, 1997
G1 control gene status is frequently altered in resectable non-small cell lung cancerD C Betticher, G R White, S Vonlanthen, et al.
British Journal of Cancer|September 14, 2006
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancerS C White, P Lorigan, G P Margison, et al.
British Journal of Cancer|June 1, 1988
A phase I and pharmacokinetic study of amphethinileD B Smith, C Ewen, J Mackintosh, et al.
Cancer|September 15, 1985
Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancerN Thatcher, R D James, W P Steward, et al.
British Journal of Cancer|July 31, 2008
Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancerS Baka, R Califano, R Ferraldeschi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2006
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancerS Baka, C Manegold, E Buchholz, et al.
British Journal of Cancer|September 2, 2005
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinomaF Donskov, M Middleton, K Fode, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patientsH Sharma, N Thatcher, J Baer, et al.
Pageof 29